The findings of this study indicate that veldoreotide is an SSA with full agonist activity at the SST4 receptor along with the SST2 and SST5 receptors as assessed by a fluorescence-based membrane potential assay in a HEK293 human embryonic kidney cell line and a BON-1 human pancreatic neuroendocrine tumor cell line. This evidence concerns the gene SSTR2 and pancreatic neuroendocrine tumor.